BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36725697)

  • 1. Preoperative radiotherapy with concomitant chemotherapy in extremity soft tissue sarcomas: long-term results of a single center.
    Yilmaz U; Kamer S; Kaya H; Sabah D; Sanli UA; Tamsel I; Yaman B; Akalin T; Anacak Y
    Strahlenther Onkol; 2023 Jun; 199(6):585-594. PubMed ID: 36725697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study.
    Bonvalot S; Wunder J; Gronchi A; Broto JM; Turcotte R; Rastrelli M; Papai Z; Radaelli S; Lindner LH; Shumelinsky F; Cubillo A; Rutkowski P; Demaire C; Strens D; Nalbantov G
    Eur J Surg Oncol; 2021 Aug; 47(8):2166-2172. PubMed ID: 33676792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
    Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
    Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wound complications are a predictor of worse oncologic outcome in extremity soft tissue sarcomas.
    Dadras M; Koepp P; Wallner C; Wagner JM; Sogorski A; Lehnhardt M; Harati K; Behr B
    Surg Oncol; 2020 Jun; 33():126-134. PubMed ID: 32561077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
    Look Hong NJ; Hornicek FJ; Harmon DC; Choy E; Chen YL; Yoon SS; Nielsen GP; Szymonifka J; Yeap BY; DeLaney TF; Mullen JT
    Eur J Cancer; 2013 Mar; 49(4):875-83. PubMed ID: 23092789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
    Eilber FC; Eilber FR; Eckardt J; Rosen G; Riedel E; Maki RG; Brennan MF; Singer S
    Ann Surg; 2004 Oct; 240(4):686-95; discussion 695-7. PubMed ID: 15383796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soft Tissue Sarcomas of the Extremities: Surgical Margins Can Be Close as Long as the Resected Tumor Has No Ink on It.
    Harati K; Goertz O; Pieper A; Daigeler A; Joneidi-Jafari H; Niggemann H; Stricker I; Lehnhardt M
    Oncologist; 2017 Nov; 22(11):1400-1410. PubMed ID: 28739867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.
    Pennington JD; Eilber FC; Eilber FR; Singh AS; Reed JP; Chmielowski B; Eckardt JJ; Bukata SV; Bernthal NM; Federman N; Nelson SD; Dry SM; Wang PC; Luu M; Selch MT; Steinberg ML; Kalbasi A; Kamrava M
    Am J Clin Oncol; 2018 Dec; 41(12):1154-1161. PubMed ID: 29664796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution.
    Pisters PW; Patel SR; Varma DG; Cheng SC; Chen NP; Nguyen HT; Feig BW; Pollack A; Pollock RE; Benjamin RS
    J Clin Oncol; 1997 Dec; 15(12):3481-7. PubMed ID: 9396401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
    Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
    Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.
    Mullen JT; Hornicek FJ; Harmon DC; Raskin KA; Chen YL; Szymonifka J; Yeap BY; Choy E; DeLaney TF; Nielsen GP
    Cancer; 2014 Dec; 120(23):3676-82. PubMed ID: 25081640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence.
    Liu CY; Yen CC; Chen WM; Chen TH; Chen PC; Wu HT; Shiau CY; Wu YC; Liu CL; Tzeng CH
    Ann Surg Oncol; 2010 Aug; 17(8):2102-11. PubMed ID: 20217247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma.
    Kobus M; Roohani S; Ehret F; Flörcken A; Striefler JK; Brandes F; Märdian S; Rau D; Wittenberg S; Öllinger R; Kaul D
    Radiat Oncol; 2022 Aug; 17(1):139. PubMed ID: 35941656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
    Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
    Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
    Mullen JT; Kobayashi W; Wang JJ; Harmon DC; Choy E; Hornicek FJ; Rosenberg AE; Chen YL; Spiro IJ; DeLaney TF
    Cancer; 2012 Aug; 118(15):3758-65. PubMed ID: 22180344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
    Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
    Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases].
    Moureau-Zabotto L; Thomas L; Bui BN; Chevreau C; Stockle E; Martel P; Bonneviale P; Marques B; Coindre JM; Kantor G; Matsuda T; Delannes M
    Cancer Radiother; 2004 Oct; 8(5):279-87. PubMed ID: 15561593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
    Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
    Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
    JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
    Wang B; Yu X; Xu S; Xu M
    Medicine (Baltimore); 2016 Jan; 95(4):e2611. PubMed ID: 26825914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.